Window-of-opportunity proof-of-concept, non-randomized, open-label phase II trial of Olaparib given alone (cohort A) or in
combination with Durvalumab (cohort B) prior to primary debulking
surgery in histologically proven high-grade epithelial ovarian
cancer (EOC)
Window-of-opportunity proof-of-concept, non-randomized, open-label phase II trial of Olaparib given alone (cohort A) or in
combination with Durvalumab (cohort B) prior to primary debulking
surgery in histologically proven high-grade epithelial ovarian
cancer (EOC)
